Neurology

Treating patients’ stress and poor sleep may help reduce the risk of depression in multiple sclerosis.

A phase 1 trial evaluating the safety and tolerability of PRN2246, a Bruton's tyrosine kinase (BTK) inhibitor, found the drug having no serious medication-related adverse events in healthy volunteers while also being able to reach the brain.

Botox injections found to decrease urinary incontinence and improve quality of life for patients with multiple sclerosis.

A protein that regulates the formation of myelin sheaths may lead to new treatments for multiple sclerosis.

New formulation of gene-silencing drug may effectively treat amyotrophic lateral sclerosis.

A recent study analyzed the role of purinergic receptor P2X4 in microglia/macrophages during autoimmune inflammation.

While the prevalence of neurological disabilities among children with HIV has drastically decreased since the emergence of antiretroviral therapy, the prevalence remains higher in this patient population

Top news of the week from Specialty Pharmacy Times.

Interferon regulatory factor 2 binding protein-like gene is essential for neurological development and maintenance.

In a groundbreaking new study, researchers have identified a molecular pathway for stimulating the regeneration of new myelinating cells, and repairing the damage of debilitating neurological diseases.

Study finds that several multiple sclerosis drug candidates inhibit the same enzyme to stimulate myelin regeneration.

Blocking the protein receptor, muscarinic type 3, may be effective in promoting remyelination in patients with multiple sclerosis.

Using targeted therapies in patients with gliobastoma who have the mutation may reduce tumor growth and improve survival outcomes.

Mapping iron concentration in certain regions of the brain may help predict multiple sclerosis progression risk.

New research has associated certain health problems with later diagnosis of multiple sclerosis.

The investigational treatment could benefit patients with amyotrophic lateral sclerosis whose disease is caused by mutations in the SOD1 gene.

Supplementation of the protein in the nerve cells prevented nerve degeneration, muscle atrophy, and paralysis in an amyloid lateral sclerosis mouse model.

Most individuals with multiple sclerosis experience pain as a symptom of the disease.

Researchers aim to determine whether an annual brain volume loss rate of less than 0.4% is a valid marker to assess treatment response.

Cognitive impairment is present in up to 70% of patients with multiple sclerosis, but can be difficult to completely evaluate in routine clinical practice.

Research to explore whether intermittent fasting can improve symptoms in patients with relapsing-remitting multiple sclerosis.

Multiple sclerosis risk increased significantly in individuals with occupational exposure to organic solvents.

IncobotulinumtoxinA is the first and only neurotoxin approved for this indication in the United States.

Two recent studies examined the different effects and aspects of progressive multiple sclerosis.

Two recent clinical trials evaluated the efficacy of the drug ozanimod, an investigational drug for the treatment of relapsing multiple sclerosis.